Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection

J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):425-427. doi: 10.1097/MPG.0000000000001838.


Recently, sofosbuvir and the fixed-dose combination of sofosbuvir/ledipasvir were approved for the treatment of chronic hepatitis C virus infection in adolescents, criteria being 12 years old and above or weighing at least 35 kg. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic hepatitis C virus and treated with dual sofosbuvir/daclatasvir therapy for a response-tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not. All patients achieved vRVR at week 2 and completed the shortened 8 weeks course. All patients (10/10) (100% [confidence interval 72.25-100%]) achieved sustained vRVR at week 12 post-treatment with good tolerability and no serious adverse events. These data could provide support to our suggested response-tailored protocol of dual therapy with sofosbuvir/daclatasvir in adolescents particularly for shortened duration in those who achieved vRVR. Further larger randomized controlled studies are recommended.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / therapeutic use
  • Child
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Imidazoles / administration & dosage*
  • Imidazoles / therapeutic use
  • Male
  • Pilot Projects
  • Prospective Studies
  • Sofosbuvir / administration & dosage*
  • Sofosbuvir / therapeutic use
  • Treatment Outcome


  • Antiviral Agents
  • Imidazoles
  • daclatasvir
  • Sofosbuvir